# Diabetes Research Hub — Monitor Report
**Run date:** 2026-07-18 (automated, unattended)
**Data vintage:** Latest script outputs are from 2026-07-17 02:05–03:08. No 2026-07-18 script run has occurred yet — the daily scripts run ~02:00 and this monitor run precedes today's refresh.

---

## Executive Summary (what's actionable)

1. **No new trial results posted overnight, but 6 trials changed status over the past week** — most notably three AstraZeneca elecoglipron Phase 3 studies flipped NOT_YET_RECRUITING → RECRUITING. Worth logging in the tracker.
2. **Breaking (web): Lilly ACHIEVE-3 reported orforglipron superior as an oral GLP-1 for T2D; Sana published new gene-edited islet durability data (Jul 13).** Both intersect our Tier 1 areas.
3. **Data-integrity flag:** `literature_gap_data.json` is **truncated** (ends mid-object, line 4634). The human-readable `literature_gap_report.md` generated fine, but the underlying data file is corrupt and should be regenerated.
4. **`zimislecel` returned 0 recent PubMed hits** despite being a tracked headline therapy — likely a query-term issue (papers may use "VX-880" or "Vertex islet"). Recommend checking the alert query.

---

## File System Status

All five key outputs are present and fresh (1 day old):

| File | Modified | Size | Status |
|------|----------|------|--------|
| hub_monitor_report.md | 2026-07-17 02:16 | 5.3 KB | OK |
| clinical_trials_latest.json | 2026-07-17 02:05 | 580 KB | OK |
| pubmed_recent_latest.json | 2026-07-17 02:06 | 121 KB | OK |
| literature_gap_data.json | 2026-07-17 02:16 | 124 KB | **TRUNCATED — regenerate** |
| literature_gap_report.md | 2026-07-17 03:08 | 11.6 KB | OK |

Snapshots are current: daily `clinical_trials_snapshot_*` and `pubmed_recent_snapshot_*` files exist through 2026-07-17. Prior monitor reports exist through 2026-07-17 (unbroken daily cadence).

Note: hub_monitor.py's own review flag reports **827 result files older than 14 days** and **1057 files tracked total** — the Results folder is accumulating many dated `agent_state.json.bak_*` and snapshot files. Not urgent, but a cleanup/archival pass would reduce clutter (see Recommended Actions).

---

## Clinical Trial Changes

**Corpus:** 858 active trials tracked (up from 852 a week ago).
Category breakdown: T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 76 · T2D Novel Therapies (Ph2-3) 147 · Diabetes Technology 236 · Recently Completed w/ Results 321.

### Overnight (07-16 → 07-17, per hub_monitor)
1 new trial, 1 removed, 0 status changes, 0 new results.

### Week-over-week (07-10 → 07-17)
**8 new trials appeared, 2 removed, 6 status changes, 0 newly-posted results (has_results flips).**

Status changes (all point toward more active recruitment):

| NCT | Change | Phase | Trial |
|-----|--------|-------|-------|
| NCT07662135 | NOT_YET → RECRUITING | Ph3 | AstraZeneca elecoglipron efficacy/safety |
| NCT07662044 | NOT_YET → RECRUITING | Ph3 | AstraZeneca elecoglipron (alone or combo) |
| NCT07662109 | NOT_YET → RECRUITING | Ph3 | AstraZeneca elecoglipron |
| NCT07662213 | NOT_YET → RECRUITING | Ph3 | Elecoglipron (study drug efficacy) |
| NCT07668388 | NOT_YET → RECRUITING | Ph2 | Novo Nordisk monlunabant/dose-comparison |
| NCT07215312 | RECRUITING → ACTIVE_NOT_RECRUITING | Ph2 | Lilly LY3938577 in T2D |

*Takeaway:* AstraZeneca has moved its **elecoglipron** (oral GLP-1) Phase 3 program into active recruitment across ≥4 studies this week — a new competitor entering the oral-incretin Phase 3 race alongside Lilly (orforglipron) and Novo (CagriSema/amycretin). Relevant to Tier 1 Clinical Trial Intelligence (combination/competitive mapping).

### Key-organization Phase 3 status (Vertex / Lilly / Novo / Sana)
- **Vertex VX-880 (zimislecel):** two Phase 3 trials RECRUITING (NCT06832410, NCT04786262); VX-264 (encapsulated) Ph1/2 active-not-recruiting.
- **Lilly:** orforglipron master protocol + multiple Ph3 (retatrutide, tirzepatide, baricitinib T1D beta-cell) active. Baricitinib NCT07222332 / NCT07222137 recruiting.
- **Novo Nordisk:** CagriSema Ph3 (NCT07564414 recruiting; others active), insulin icodec Ph3 recruiting.
- **Sana:** not surfaced in ClinicalTrials.gov key-org filter this cycle (Sana's HIP islet work is early/investigator-stage) — but see Breaking News: new publication Jul 13.

### Recently posted results worth reviewing (from `results_posted`)
- **NCT05086445** (2026-07-16) — Lilly orforglipron (LY3502970) in Japanese T2D participants, Phase 1.
- **NCT05574699** (2026-07-15) — Social Risk Score + CDS + closed-loop referral (health-equity/AP crossover).
- **NCT05254002** (2026-07-13) — Bayer finerenone combination study, Phase 2.
- **NCT04255433** (2026-07-08) — Lilly tirzepatide vs dulaglutide **MACE** outcomes, Phase 3 (cardiovascular — high value).

---

## PubMed Highlights

**158 unique papers**, 30-day lookback, 16 alert domains queried (per `pubmed_recent_latest.json`).

### Cross-domain papers (highest value — appear in ≥2 domains)
12 identified. Standouts:
- **[42459945]** "A framework for assessing algorithmic discrimination risks in training data: pediatric type 1 diabetes" — **3 domains** (AI/ML, Closed Loop AP, Health Equity). Directly on the AI/ML × Health Equity seam we flag as a gap.
- **[42419792]** "Comparative effects of drugs for adults with overweight/obesity: systematic review" — spans orforglipron + retatrutide + CagriSema (competitive-landscape synthesis).
- **[42411999]** "Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic [transplant]" — Stem Cell Cure × Immunotherapy.
- **[42453334]** "Noncoding RNAs for Diabetes Research" — Biomarker × LADA.
- **[42458730]** & **[42459212]** — two Microbiome × Multi-Omics papers (both new this cycle; relevant to Tier 1 Multi-Omics).

### Key-therapy activity (matched papers, 30 days)
| Therapy | PubMed matches |
|---------|----------------|
| dapagliflozin | 52 |
| orforglipron | 10 |
| CagriSema | 6 |
| retatrutide | 4 |
| teplizumab | 4 |
| icodec | 3 |
| baricitinib | 2 |
| **zimislecel** | **0** ⚠ |

*`zimislecel` = 0 is almost certainly a terminology mismatch (literature still uses "VX-880").* Recommend adding "VX-880" as an alias in the alert query.

### Publication-volume signal (matched counts, capped capture at 10/domain)
Hottest: Diabetes AI/ML (260), Microbiome (186), T2D GLP-1 New (167), Biomarker (166).
Quietest: GLP-1 Pharmacogenomics (1), Epigenetics (5), Drug Repurposing (8), LADA (12) — the quiet domains overlap our under-researched-gap list below.

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (30 domains, 435 pairs, corpus 2020–2026). Top 5 reliable under-researched intersections (gap score 100 = ~zero joint papers vs. an independence model):

| Rank | Intersection | Expected joint | Found | Tier-1 alignment |
|------|-------------|----------------|-------|------------------|
| 1 | GWAS/Polygenic × Closed Loop/AP | 25.4 | 0 | AI/ML Prediction + Multi-Omics |
| 2 | Drug Repurposing × CGM Technology | 10.2 | 0 | **Drug Repurposing (Tier 1 #4)** |
| 3 | Treg/CAR-T × Neuropathy | 7.5 | 0 | — |
| 4 | Beta Cell Regen × Health Equity | 7.3 | 0 | **Health Equity (Tier 1 #6)** |
| 5 | Treg/CAR-T × Health Equity | 4.7 | 0 | **Health Equity (Tier 1 #6)** |

**Tier-1-aligned opportunities:** Ranks 2 (Drug Repurposing), 4 & 5 (Health Equity), plus #10 (Drug Repurposing × Health Equity) and #6 (Glucokinase × Health Equity) sit squarely in our declared highest-value areas. The **Drug Repurposing × CGM** and **Beta Cell Regen × Health Equity** gaps are the strongest "we have the tools and the mandate" candidates for a first computational contribution.

⚠ The underlying `literature_gap_data.json` is truncated — the report above is trustworthy for this run, but re-run the analysis to restore a clean data file before building on it.

---

## Breaking News (web, ~last 7 days) — [Likely], from secondary coverage

Genuinely significant items only:

- **Lilly ACHIEVE-3 — orforglipron reported superior as an oral GLP-1 RA for T2D.** Reinforces the oral-incretin momentum; pairs with the NCT05086445 Japanese Ph1 results posted 07-16 and the orforglipron master protocol.
- **Sana — new gene-edited islet durability publication (Jul 13, 2026): transplanted cells continuing to produce insulin.** Directly relevant to our T1D Cure & Cell Therapy category (152 trials) and to the zimislecel/islet-transplant space. *Note the contrast with our PubMed alert missing cell-therapy signal this cycle.*
- **Novo PIONEER TEENS — oral semaglutide superior glycemic control in pediatric T2D** (presented ADA 2026).
- **FDA / Tzield (teplizumab):** new pediatric indication (ages 8–17, recently-diagnosed Stage 3 T1D) granted **Jun 12, 2026** — first approval for that indication. Aligns with Lilly/Sanofi baricitinib & teplizumab Ph3 prevention trials we track.
- **Watch item:** Lilly **insulin efsitora alfa** FDA decision reportedly expected **July 2026** — no confirmed action found; check next run.

*Confidence:* [Likely] — sourced from trade/secondary coverage via web search, not primary press releases or journal DOIs. Verify against primary sources before citing in any deliverable (per Research Doctrine evidence standards, treat as Bronze until a primary source is attached).

---

## Recommended Actions

1. **Regenerate the corrupt gap data file:** `python project1_literature_gap_analysis.py` — `literature_gap_data.json` is truncated. (The .md report is fine, but the data file feeds downstream dashboards.)
2. **Fix the zimislecel alert:** add "VX-880" (and possibly "islet cell therapy Vertex") as query aliases in `baseline_pubmed_alerts.py`; 0 hits is a false negative given active Ph3 recruitment.
3. **Log the 6 week-over-week status changes** in `Diabetes_Research_Tracker.xlsx`, especially the AstraZeneca elecoglipron Ph3 program entering recruitment (new oral-GLP-1 competitor).
4. **Review high-value posted results:** NCT04255433 (tirzepatide vs dulaglutide **MACE**, Ph3) and NCT05254002 (finerenone combo) — cardiovascular/combination signal for Clinical Trial Intelligence.
5. **Prioritize a Tier-1 gap for a first computational pass:** Drug Repurposing × CGM Technology (gap #2) or Beta Cell Regen × Health Equity (gap #4) — both align with declared Tier 1 areas and have public data.
6. **Verify breaking-news items against primary sources** (ACHIEVE-3 readout, Sana Jul-13 paper DOI, efsitora FDA action) before promoting from Bronze/[Likely] to a cited claim.
7. **Housekeeping (non-urgent):** 827 result files >14 days old; consider archiving old `agent_state.json.bak_*` and pre-July snapshots to a subfolder to keep Results navigable.

---

## Verification Notes
- Trial counts, status changes, and results dates were computed directly from `clinical_trials_latest.json` and the 07-10/07-17 snapshots via structured `jq` queries (not estimated).
- PubMed figures read directly from `pubmed_recent_latest.json` (`domain_results`, `therapy_hits`, cross-domain `papers`).
- Gap rankings quoted verbatim from `literature_gap_report.md`; the companion `.json` was confirmed truncated by tail inspection.
- Breaking-news items are [Likely] (secondary web sources) and explicitly flagged for primary-source verification.
- This was a **read-only review run** — no existing files were modified.

*Generated by diabetes-hub-monitor scheduled task — 2026-07-18*

Sources (web): [ADA 2026 / trial coverage — HCPLive](https://www.hcplive.com/view/ada-scientific-sessions-2026-preview-6-trials-to-know) · [Type 1 breakthroughs 2026 — Type1Strong](https://www.type1strong.org/blog-post/type-1-diabetes-breakthroughs-to-watch-in-2026) · [FDA Tzield (teplizumab) pediatric indication](https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-tzield-teplizumab-certain-pediatric-patients-recently-diagnosed-stage-3) · [FDA decisions expected July 2026 — Prime Therapeutics](https://www.primetherapeutics.com/fda-decisions-expected-july-2026)
